Alector Stock Price, News & Analysis

Alector (Nasdaq: ALEC) announced a virtual R&D event scheduled for September 22, 2025, focusing on their progranulin (PGRN) franchise and Alector Brain Carrier (ABC) programs. The presentation will highlight two key clinical programs: latozinemab, in Phase 3 trials for frontotemporal dementia, and AL101, in Phase 2 trials for early Alzheimer's disease.

The event will also showcase preclinical data from their ABC-enabled programs, including a brain-penetrant anti-amyloid beta antibody for Alzheimer's and a GCase-enzyme replacement therapy for Parkinson's disease. Additionally, updates on ABC-enabled siRNA programs will be presented, demonstrating the platform's versatility in treating neurodegenerative diseases.

Alector (NASDAQ: ALEC), a late-stage clinical biotechnology company specializing in neurodegeneration therapies, has announced its participation in three upcoming healthcare investor conferences in September 2025.

The company will present at the Cantor Global Healthcare Conference on September 4 at 3:55 p.m. ET, the Morgan Stanley Global Healthcare Conference on September 8 at 10:00 a.m. ET, and the H.C. Wainwright Global Investment Conference on September 9 at 1:30 p.m. ET. All presentations will be available via webcast on Alector's investor relations website, with replays accessible for 90 days.

Alector (NASDAQ:ALEC), a late-stage clinical biotech company, reported Q2 2025 financial results and business updates. The company maintains a strong financial position with $307.3 million in cash, providing runway into H2 2027. Key highlights include the upcoming topline data from the INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN expected by mid-Q4 2025, with potential BLA submissions in 2026.

Q2 2025 financial results showed collaboration revenue of $7.9 million (down from $15.1M in Q2 2024), R&D expenses of $27.6 million (down from $46.3M), and a net loss of $30.5 million. The company updated its 2025 guidance, projecting collaboration revenue between $13-18 million, R&D expenses of $130-140 million, and G&A expenses of $55-65 million.

The company continues advancing its pipeline, including the Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease and development of brain-penetrant candidates through its proprietary Alector Brain Carrier platform.

Alector (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on neurodegeneration therapies, will host its Q2 2025 earnings conference call on Thursday, August 7, 2025, at 4:30 p.m. ET.

The call will feature Dr. Ryan Darby, Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will discuss unmet needs in frontotemporal dementia. The company will release its Q2 2025 financial results before the call.

Participants can access the webcast through Alector's investor relations website, with a 30-day replay available afterward. Phone participants must register online to receive dial-in details.

Alector announced that CFO Marc Grasso will leave the company on June 20, 2025, with Chief Business Officer Neil Berkley stepping in as Interim CFO while maintaining his current role. The company, which focuses on developing neurodegeneration therapies, has a strong financial position with cash runway extending into H2 2027. Alector is advancing two late-stage clinical candidates in partnership with GSK: latozinemab for FTD-GRN, with topline Phase 3 data expected in Q4 2025, and AL101 for early Alzheimer's, which completed Phase 2 enrollment in April 2025. The company continues developing its proprietary blood-brain barrier technology platform (ABC), including programs for Alzheimer's and Parkinson's disease.

Alector (NASDAQ: ALEC), a late-stage clinical biotechnology company specializing in neurodegeneration therapies, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, June 10, 2024, at 8:40 am ET. Investors can access a live webcast of the discussion through Alector's website investor section, with a replay available for 90 days following the event. The company focuses on developing treatments to combat neurodegenerative disease progression.

Alector (NASDAQ: ALEC) reported Q1 2025 financial results and provided business updates. The company maintains $354.6 million in cash, extending runway into H2 2027. Key highlights include: topline data from INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN expected in Q4 2025, completed enrollment in PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's, and advancement of Brain Carrier programs. Q1 financials show revenue of $3.7 million (down from $15.9M in Q4 2024), R&D expenses of $33.6 million (down from $45.2M), and net loss of $40.5 million ($0.41 per share). The company maintains its 2025 guidance with expected collaboration revenue of $5-15M, R&D expenses of $175-185M, and G&A expenses of $55-65M.

Alector (NASDAQ: ALEC), a late-stage clinical biotechnology company specializing in neurodegeneration therapies, has announced its participation in two upcoming healthcare investor conferences. The company will deliver a corporate presentation at the Bank of America Securities Health Care Conference in Las Vegas on May 13, 2025, at 2:20 p.m. PT. Additionally, Alector will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025, at 12:00 p.m. ET. Both presentations will be available via webcast on Alector's investor relations website, with replays accessible for 90 days following the events.

Alector (Nasdaq: ALEC) has completed enrollment ahead of schedule for its PROGRESS-AD Phase 2 clinical trial, evaluating AL101/GSK4527226 in early Alzheimer's disease patients. The 76-week trial, conducted in partnership with GSK, aims to assess the safety and efficacy of AL101 in slowing disease progression.

AL101 is an investigational human monoclonal antibody designed to elevate progranulin (PGRN) levels in the brain by blocking the sortilin receptor. Research has shown that reduced PGRN levels from GRN gene mutations increase Alzheimer's risk, while elevated PGRN levels demonstrate protective effects in animal models.

The randomized, double-blind, placebo-controlled study is evaluating two dose levels of AL101 administered intravenously. The trial's primary endpoint measures disease progression using the Clinical Dementia Rating Sum of Boxes (CDR®-SB), a validated instrument tracking cognitive impairments.